Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

The Download: autonomous narco submarines, and virtue signaling chatbots

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The Download: autonomous narco submarines, and virtue signaling chatbots Date: 2026-02-19 13:10 Source: https://www.technologyreview.com/2026/02/19/1133339/the-download-autonomous-narco-submarines-and-virtue-signaling-chatbots/ <p><em>This is today’s edition of <a href="https:…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Morally, there's an ironclad case that countries or companies responsible for climate emissions should provide compensation

    80% confidence
  • The United States and European Union grew into economic superpowers by committing climate atrocities, burning a wildly disproportionate share of the world's oil and gas

    80% confidence
  • Uncrewed narco submarines could move more cocaine over longer distances without putting human smugglers at risk of capture

    80% confidence
  • Removing beauty filters may have impinged on free expression

    80% confidence
  • Too often, victims have been left to fight alone. That is not justice. It is failure.

    80% confidence
  • An AI-based tool can help surrogates predict what patients themselves would want in end-of-life decision situations

    80% confidence
  • The moral behavior of large language models should be scrutinized with the same kind of rigor as their ability to code or do math

    80% confidence
  • Nobody knows how trustworthy LLM technology really is at sensitive tasks as people ask them to play more sensitive roles and agents take actions on their behalf

    80% confidence
  • Increasing engagement is not Instagram's goal; the company's true calling is to give its users something useful

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com